Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$DSCR: Hemp Process
$IDGC: ID Global Corporation Provides an Investment Portfolio Update
Date : 05/08/2014 @ 12:12PM
Source : PR Newswire (US)
Stock : Idglobal Corp. (PC) (IDGC)
CHICAGO, May 8, 2014 /PRNewswire/ -- ID Global Corp. (OTC: IDGC) is pleased to provide an investment portfolio update to its shareholders. This update includes new assets, adding to its current portfolio, which includes a new assignment of claims for Physicians Healthcare Management Group (OTC:PHYH):
PHYH:
Acquired $358,000 of receivables.
Sebastien DuFort, president and CEO, stated, "This asset acquisition is consistent with our new long-term strategy shared by Robert Trinka, Chairman and CEO of PHYH. We are pleased to have been able to step in and provide the assistance, for the mutual benefit of both companies."
About Physicians Healthcare Management Group, Inc.
Physicians Healthcare Management Group, Inc. (PHYH) is a holding company focusing on employing its management and capital resources in early-stage growth companies that seek to benefit from the public markets, but lack the public company management expertise and financial resources to comply with regulatory requirements of a publicly traded company, without our assistance. PHYH will target companies that have the right growth and profit characteristics covering a wide range of industries.
- Go IDGC
$DSCR: Discovery Provides Update on Hemp Seed, Files Quarterly Disclosure Statement
Date : 06/26/2014 @ 9:30AM
Source : PR Newswire (US)
Stock : Discovery Minerals Ltd. (PC) (DSCR)
MARINA DEL REY, Calif., June 26, 2014 /PRNewswire/ -- Discovery Minerals LTD. (OTC Pink: DSCR) (OTC: DSCR) has posted an informative new Bio-Fuel Flip Book at: discoveryholdingscorp.com/content/biofuels.
This interactive flipbook describes the challenges surrounding Bio-Fuel production, and illustrates how PlusWave Technology enhances Bio-Fuel production using hemp.
The Hemp seed has been prepped and loaded into the air seeder, and will be planted as soon as weather conditions are favorable. Discovery looks forward to updating investors with photos once seeding starts. One of the many benefits to the CRS-1 variety is its shorter growing cycle.
Discovery has also posted quarterly financial filings for the period ending March 31, 2014. The Quarterly Disclosure Statement is now available on the OTC web site at: www.otcmarkets.com/stock/DSCR/financials.
About Discovery Minerals LTD.
Discovery Minerals Ltd., (OTC PINKSHEETS: DSCR.PK) is an acquisition and development company that targets natural resource properties through its subsidiaries. These properties fall within two primary channels, precious metals/mining and industrial hemp. Discovery subsidiaries engage in activities that include the cultivation, product development, and distribution of industrial hemp; Gold, silver and precious metals. In addition, the Company is pursuing clean tech and alternative energy investments to be integrated into these business channels.
- Go DSCR
$DSCR: Discovery Joint Ventures Hemp Seed Arrives
Date : 06/24/2014 @ 8:00AM
Source : PR Newswire (US)
Stock : Discovery Minerals Ltd. (PC) (DSCR)
MARINA DEL REY, Calif., June 24, 2014 /PRNewswire/ -- Discovery Minerals LTD. (OTC Pink: DSCR) (OTC: DSCR) is pleased to announce that 3,900 pounds of Hemp Seed has arrived at the growing partner's farm and will be planted immediately, or as weather permits. To ensure an adequate reserve is in place, an additional 200 pounds of seed was ordered. AB AGRO and Discovery will keep investors updated on the crops progress. Photos and video will be posted on the Company's web site as they become available.
About Discovery Minerals LTD.
Discovery Minerals Ltd., (PINKSHEETS: DSCR) is an acquisition and development company that targets natural resource properties through its subsidiaries. These properties fall within two primary channels, precious metals/mining and industrial hemp. Discovery subsidiaries engage in activities that include the cultivation, product development, and distribution of industrial hemp; Gold, silver and precious metals. In addition, the Company is pursuing clean tech and alternative energy investments to be integrated into these business channels.
- Go DSCR
46 Reason Why CANLF Will Succeed, great article.
http://www.stockhouse.com/companies/bullboard/c.can/cannabis-technologies-inc?postid=22781981
CANLF, a very Unique Biotech opportunity. Here's several links to help better educate everyone on the Company, worth the read.
http://www.marketwatch.com/story/cannabis-technologies-a-junior-gw-play-on-cannabinoids-potential-2014-06-25
http://www.cannabisfn.com/advocate-cheryl-shuman-discusses-cbd-benefits-and-cannabis-technologies-on-ctv-interview/#.U854V_RDtvB
CTIX DD-Catalysts-Brilicidin-Anitbiotic Wonderdrug?
Possible BTD for B-Defensin Mimetic Antibiotic-No human resistance. If B rivals Daptomycyn and the mechanism of action does not allow for resistance-WATCH OUT!
July 2014-Possible PR's
1. B-ABSSSI interim report
2. B-ABSSSI enrollment complete
3. B-OM INDA
4. K cohort 8 dosing start
5. P phase 1 report
Resistance to Daptomycin is on the rise as the usage of this antibiotic increases.
http://cid.oxfordjournals.org/content/40/7/1058.long
Brilacidin PR within 1-2 weeks after the interim data is collected. Possible BTD before year end.
We know from the phase 2 B Polymedix data that all 3 arms produced significant clinical results for skin and soft tissue infections.
This new class of antibiotics, in which Brilacidin is the prototype should not be subject to bacterial resistance.
For this reason alone, Brilacidin may shoot to drug of choice status.
"* Kevetrin Phase 1 entering 8th Cohort with no prior phase 1 limiting DLTs or MTD yet observed. Dosing now into the higher of the anticipated efficacy range. Cohort 8 215MG, 33% increase. Possible MTD by cohort 9/10
* K in combination against renal completed most if not all preclinical work done.
* K in combination against leukemia (AML) already [completed] preclinical work at UofB and a Phase 1b/2 Clinical Trial is poised to start
* K against Retinoblastoma announced in March 2013 will commence soon
* Prurisol bridge study enrollment complete. Abracavir conversion will result in phase 2/3
* B against ABSSSI now 70% enrolled and treated NO AE's.
* Large pharma discussions underway possible announcement after July review board meeting. Possible BTD on B after review meeting or by end of trial if results match or beat Daptomycyn
* B OM completed final formulation work and expected to submit INDA to FDA.
* B ocular formulation studies underway at Dr Reddy's and should complete within the next few to 6 months.
* B otic also in formulation studies at Dr Reddy's
* B DFI just announced high efficacy and should begin final preclinical work ahead of clinical testing. "
*B NY/ NJ universities material transfer agreement defensive mimetics
*Cellceutix in June, 2014, entered into a research agreement with a renowned non-profit research institution for studies of anti-fungal compounds in Cellceutix’s portfolio. The research is to be funded by a $1.5 million grant from the National Institute of Health, Small Business Innovation Research (SBIR) to the non-profit institution
Biotech Implications for Quantum Dots..Emerging Nanotechnology.
Quantum Materials Exhibitor & Invited Speaker Molecular Medicine Tri-Conference, Moscone Center, San Francisco, February 11-13 2013. Mr Squires Topic, Tetrapod Quantum Dot's Applications in Emerging Nano Molecular Medicine & Diagnostics, Ranging from Imaging Assays, Multiplex Drug Delivery & Cellular Targeting Platforms.
Quantum Dots are the future of molecular medicine and biotech, in assays, diagnostics, theranostics, drug delivery and point-of-care devices.
"Green" quantum dot synthesis approach using continuous flow chemistry mass production can dramatically lower the cost of energy transfer conjugates, while delivering better features, and more accurate results and outcomes. These quantum dots are Tetrapod shape, uniform, low cost and mass producible.
Biomedical Research assays using tetrapod quantum dots instead of chromophores and florophores have advantages of brightness, stability and reacton time for more accurate treatments & diagnosis. Quantum dots coupled with biomarkers, allow diagnosis of disease which can become point of care care devies in doctor's offices with instant readouts. Bio-compatable Tetrapod QD used in a multiplexing drug delivery platform is also being explored for diagnosis, treatment and eradication of cancer cells. For many biotech applications the ultimate "enabling technology' will be easily synthesized and scaled high quantum dot yield and uniform quantum dots.
Quantum Materials Corporation is developing specialized quantum dots for a private biotech company, Nanoaxis LLC to functionalize with their proprietary biomedical nanomaterials for a multiplexing drug delivery platform for drug/gene therapy and diagnostic medical devices technologies. Quantum Materials' CEO Stephen Squires will report on this joint alliance and our progress developing new quantum dots at the CHI Emerging Diagnostics partnership Forum in San Francisco on February 11th.
For More Information "Review of Quantum Dot Technologies for Cancer Detection and Treatment" http://www.azonano.com/article.aspx?ArticleID=1726
Quantum Materials QTMM OTC-QB is Emerging Mass Producer of Tetrapod Quantum Dots Not a p/d more L/T Investment
http://ih.advfn.com/p.php?pid=nmona&article=62623214
GSK and THRX Announce Positive Data From Two Studies Evaluating the Efficacy and Safety of ... http://finance.yahoo.com/news/gsk-theravance-announce-positive-data-114000832.html?soc_src=mediacontentstory via @YahooFinance
PTLA Portola Pharmaceuticals Announces Positive Phase 2 Data With FDA-Designated Breakthrough Therapy ... http://finance.yahoo.com/news/portola-pharmaceuticals-announces-positive-phase-120000662.html?soc_src=mediacontentstory via @YahooFinance
NWBO DCVAX-DIRECT TRIAL UPDATE INDICATES FURTHER POSITIVE RESPONSES; 3 CASE STUDIES SHOW NO LIVE TUMOR... http://finance.yahoo.com/news/dcvax-direct-trial-indicates-further-121500060.html?soc_src=mediacontentstory via @YahooFinance
ATNM Panelists at NewYorkBIO-CONference Highlight Prior Clinical Data Showing Iomab™-B Improves Surviv... http://finance.yahoo.com/news/panelists-newyorkbio-conference-highlight-prior-131500692.html?soc_src=mediacontentstory via @YahooFinance
WeedStock Conference June 29 through July 1 at the Westin Denver Downtown in Denver, Colorado
http://www.weedstockconference.com/presenters.html
AGIO Agios Pharmaceuticals Initiates Multiple Ascending Dose Trial in Healthy Volunteers of AG-348 for... http://finance.yahoo.com/news/agios-pharmaceuticals-initiates-multiple-ascending-120000669.html?soc_src=mediacontentstory
ADXS Advaxis Announces Business Update Conference Call FOR TOMORROW http://finance.yahoo.com/news/advaxis-announces-business-conference-call-113000255.html?soc_src=mediacontentstory
ALNY Alnylam Presents New Pre-Clinical Data with Development Candidate for ALN-CC5, a Subcutaneously A... http://finance.yahoo.com/news/alnylam-presents-pre-clinical-data-120000567.html?soc_src=mediacontentstory
GLMD Galmed Pharmaceuticals Announces the Filing of a Provisional Patent Application for the Use of Ar... http://finance.yahoo.com/news/galmed-pharmaceuticals-announces-filing-provisional-120000264.html?soc_src=mediacontentstory
Merck (MRK) surprised many folks Monday morning by announcing plans to acquire Idenix Pharmaceuticals (IDIX) for $3.85 billion.
IMMU Immunomedics Announces Orphan Drug Designation for IMMU-132 for Pancreatic Cancer Therapy http://finance.yahoo.com/news/immunomedics-announces-orphan-drug-designation-123000043.html?soc_src=mediacontentstory
CBST Cubist Announces Publication of Pivotal Data from SIVEXTRO™ (tedizolid phosphate) ESTABLISH-2 Cli... http://finance.yahoo.com/news/cubist-announces-publication-pivotal-data-130000074.html?soc_src=mediacontentstory
TTHI Transition Therapeutics Enters Into a Private Placement with Investors to Receive up to US$30.8 M... http://finance.yahoo.com/news/transition-therapeutics-enters-private-placement-130100657.html?soc_src=mediacontentstory
ADXS Advaxis's ADXS-cHER2 Immunotherapy Continues to Demonstrate Significantly Prolonged Survival in C... http://finance.yahoo.com/news/advaxiss-adxs-cher2-immunotherapy-continues-113000712.html?soc_src=mediacontentstory
BCLI First Patient Enrolled in BrainStorm's Phase II ALS Trial at Massachusetts General Hospital http://finance.yahoo.com/news/first-patient-enrolled-brainstorms-phase-124000617.html?soc_src=mediacontentstory
IBIO iBio European Patent on iBioModulator Technology Emerges From Opposition Period http://finance.yahoo.com/news/ibio-european-patent-ibiomodulator-technology-123100769.html?soc_src=mediacontentstory
CRIS Curis Announces Re-Initiation of Patient Dosing in CUDC-427 Monotherapy Clinical Trial http://finance.yahoo.com/news/curis-announces-initiation-patient-dosing-110000940.html?soc_src=mediacontentstory
MRNA Marina Biotech Receives Decision to Grant Japanese Patent for Its SMARTICLES Nucleic Acid Deliver... http://finance.yahoo.com/news/marina-biotech-receives-decision-grant-113000030.html?soc_src=mediacontentstory
MDGN Medgenics Announces First Patient Implanted in Phase 1/2 Clinical Trial of MDGN-201 (EPODURE) http://finance.yahoo.com/news/medgenics-announces-first-patient-implanted-123000537.html?soc_src=mediacontentstory
BHRT Bioheart to Present at the PRP and Regenerative Medicine Symposium (TOBI 2014) http://finance.yahoo.com/news/bioheart-present-prp-regenerative-medicine-120000615.html?soc_src=mediacontentstory
MTST MetaStat, Inc. Announces Publication of Results of its MetaSite Breast Test in the Journal of the... http://finance.yahoo.com/news/metastat-inc-announces-publication-results-100000387.html?
ADXS Data Published by Researchers at the National Cancer Institute Further Identifies How Advaxis's Lm-LLO Immunotherapy Eradicates Tumors http://finance.yahoo.com/news/data-published-researchers-national-cancer-120000298.html
AVXL Anavex Awarded New U.S. Patent http://finance.yahoo.com/news/anavex-awarded-u-patent-112700867.html?
ARGS Treatment With AGS-003 and Sunitinib Associated With Doubling of Expected Survival in Patients Wi... http://finance.yahoo.com/news/treatment-ags-003-sunitinib-associated-123000861.html?soc_src=mediacontentstory
AQXP Aquinox Pharmaceuticals Announces Expansion of Ongoing Phase 2 Trials of AQX-1125, Including Acce... http://finance.yahoo.com/news/aquinox-pharmaceuticals-announces-expansion-ongoing-123000630.html?soc_src=mediacontentstory
ARIA ARIAD Announces Longer-Term Safety and Efficacy Data of Ponatinib from PACE and Phase 1 Clinical ... http://finance.yahoo.com/news/ariad-announces-longer-term-safety-113000953.html?soc_src=mediacontentstory
PLPL Plandai Biotechnology, Inc. Awarded $1.3 Million Grant From South African Department of Trade & I... http://finance.yahoo.com/news/plandai-biotechnology-inc-awarded-1-130000059.html?soc_src=mediacontentstory
IMMU Immunomedics Reports IMMU-130 is Active in Patients With Irinotecan-Refractory Colorectal Cancer http://finance.yahoo.com/news/immunomedics-reports-immu-130-active-123000785.html?soc_src=mediacontentstory
LPTN Lpath to Present Trial-in-Progress Poster at ASCO Describing the ASONEP Phase 2 Clinical Trial in... http://finance.yahoo.com/news/lpath-present-trial-progress-poster-120000597.html?soc_src=mediacontentstory
BCLI Positive Interim Phase IIa ALS Data With BrainStorm's NurOwn Presented at Joint Congress of Europ... http://finance.yahoo.com/news/positive-interim-phase-iia-als-120000240.html?soc_src=mediacontentstory
BTX BioTime's Subsidiary Asterias Biotherapeutics, Inc. Announces a $14.3 Million Strategic Partnersh... http://finance.yahoo.com/news/biotimes-subsidiary-asterias-biotherapeutics-inc-123000881.html?soc_src=mediacontentstory
:( DARA BioSciences, Inc. Announces Pricing of $12.5 Million Public Offering http://finance.yahoo.com/news/dara-biosciences-inc-announces-pricing-124641447.html?soc_src=mediacontentstory
HTBX Heat Biologics Receives Green Light to Expand Enrollment of Its Phase 1/2 Study of HS-410 in Bladder Cancer Based on Encouraging Preliminary Safety Results http://finance.yahoo.com/news/heat-biologics-receives-green-light-120500050.html?soc_src=mediacontentstory
QRXPY QRxPharma Receives Complete Response Letter From FDA Regarding Moxduo® NDA http://finance.yahoo.com/news/qrxpharma-receives-complete-response-letter-100000793.html?soc_src=mediacontentstory
NVGN Novogen announces milestone with its super-benzopyran (:SBP) drug program; extended its preclinical SBP program to include prostate cancer as well as ovarian and brain cancers (NVGN) : NVGN announced that it has achieved a key milestone with its super-benzopyran (:SBP) drug program, having identified a number of SBP compounds with potent anti-cancer activity against human prostate cancer cells in vitro. As a result, Novogen has extended its preclinical SBP program to include prostate cancer as well as ovarian and brain cancers.
NBS Neostem announces grant of two U.S. patents for CD34 cell program (NBS) :
Co announced the expansion of intellectual property protection surrounding its CD34 Cell Program. That program is developing therapeutics to address ischemia, the process that occurs when the supply of oxygenated blood in the body is restricted.
The recently granted U.S. patents relate to AMR-001, the Company's most clinically advanced product candidate in its CD34 Cell Program, which is designed to treat damaged heart muscle following acute myocardial infarction.
Ebix acquires Healthcare Magic; co paid $6 mln in cash for Healthcare Magic with a contingent earn out of up to $12.5 mln payable after 2 years (EBIX) :
Co announced that it has acquired Healthcare Magic -- a medical advisory service.
Ebix will integrate the services from this acquisition into its A.D.A.M. Health Division. Ebix funded this transaction using its internal cash reserves.
The Company paid $6 mln in cash for Healthcare Magic with a contingent earn out of up to $12.5 mln payable after 2 years.
ADXS Advaxis' HER2 immunotherapy candidate receives Orphan Drug Designation for treatment of osteosarcoma (ADXS) :
Co announced that it has been granted Orphan Drug Designation (:ODD) from the FDA Office of Orphan Products Development for ADXS-cHER2 for the treatment of osteosarcoma.
"Looking ahead, Advaxis is now planning to initiate a clinical development program in pediatric osteosarcoma with ADXS-cHER2. Given the limited availability of new treatment options for pediatric osteosarcoma, we believe that, subject to regulatory approval and upon completion of successful clinical trials, the potential to be on the market may be accelerated."
CYTK Cytokinetics Announces Additional Data From BENEFIT-ALS to be Presented at the Joint Congress of ... http://finance.yahoo.com/news/cytokinetics-announces-additional-data-benefit-113202398.html?soc_src=mediacontentstory
BMRN BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Dis... http://finance.yahoo.com/news/biomarin-doses-first-patient-phase-120000434.html?soc_src=mediacontentstory
NWBO EARLY POSITIVE RESPONSES SEEN IN OVER 50% OF DCVAX®-DIRECT PATIENTS TO DATE http://finance.yahoo.com/news/early-positive-responses-seen-over-123000122.html?soc_src=mediacontentstory
Followers
|
104
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
11554
|
Created
|
09/22/09
|
Type
|
Free
|
Moderator StocksDiva | |||
Assistants |
Look for products that are at the end of the FDA approval process, the bulk of testing has been completed on these products and the only thing the sponsor is waiting for is an approval decision to allow marketing of the product. Although by this stage, success is still not guaranteed because the FDA can deny approval for any reason even if the clinical results are perfect; They may sometimes have questions on manufacturing, labeling, and so on which could delay approval of the product.
Remember to always watch fda's and bio tech stocks very close, Keep track of the RSI...when it starts dropping...sell sell sell
Time lines on FDA approval stocks generally has a very slim window of opportunity for making you profits. I have gathered a time breakdown of data to show you how quickly they come into play and without delay go downward just as fast. This particular stock opened the day at 9:30 am ET at .70 with only 300 in volume. She sat idle all trading day and as illustrated when the news hit at 2:59 pm ET, she took off like a house on fire.
By 3:06 pm ET, word got around that she was approved and by 3:08 pm ET she peaked and by 3:09 pm ET, she started her downward slope. Generally once BioTech stock with FDA approval starts her descent, you don't want to contemplate of whether to hold her, GET GREEN and GET GONE! Lesson learned or you might be waiting a long time for a companies pipeline to come around again.
TIME and Sales to the end:
4:00 PM 1.07 220,854 | 3:31 PM 1.04 170,480 | 3:12 PM 1.30 137,912 |
3:59 PM 1.07 215,854 | 3:29 PM 1.00 170,362 | 3:11 PM 1.30 137,412 |
3:56 PM 1.07 214,854 | 3:24 PM 1.02 165,362 | 3:09 PM 1.425 135,712 |
3:54 PM 1.07 210,854 | 3:21 PM 1.04 154,412 | |
3:51 PM 1.02 210,654 | 3:19 PM 1.10 148,412 | 3:08 PM 1.50 129,022 |
3:49 PM 1.02 204,980 | 3:17 PM 1.02 143,292 | 3:07 PM 1.32 122,772 |
3:46 PM 1.02 199,980 | 3:16 PM 1.10 140,692 | Resisted |
3:44 PM 1.02 187,480 | 3:14 PM 1.15 138,662 | 3:06 PM 1.25 120,372 |
3:42 PM 1.03 182,980 | 3:13 PM 1.25 138,412 | 3:04 PM 1.00 114,872 |
3:41 PM 1.03 181,480 | Started back down | 3:03 PM 1.08 97,572 |
3:40 PM 1.03 179,980 | 3:02 PM 1.01 591,522 | |
3:35 PM 0.99 178,980 | 3:01 PM 0.74 54,060 | |
3:32 PM 0.88 176,480 | 3:00 PM 0.70 29,526 |
NEWS that made it run fast & furious Ophthalmic Imaging Systems Receives FDA Clearance to Market Revolutionary New Portable Digital Imaging Device
November 30, 2009:
02:59 PM ET (THIS IS WHERE THE APPROVAL NEWS STARTED)
9:30 AM 0.70 300 (BEGINING OF TRADE DAY)
Love them as much as they Love us....They are Coming HOME!!!
Thanks for the memories and the support...You all know who I am talking about:)
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |